Matches in Wikidata for { <http://www.wikidata.org/entity/Q98603674> ?p ?o ?g. }
Showing items 1 to 34 of
34
with 100 items per page.
- Q98603674 description "clinical trial" @default.
- Q98603674 description "ensayo clínico" @default.
- Q98603674 description "ensayu clínicu" @default.
- Q98603674 description "klinisch onderzoek" @default.
- Q98603674 description "клінічне випробування" @default.
- Q98603674 description "կլինիկական փորձարկում" @default.
- Q98603674 description "临床试验" @default.
- Q98603674 name "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 name "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 type Item @default.
- Q98603674 label "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 label "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 prefLabel "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 prefLabel "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 P1132 Q98603674-30840E04-CE63-4689-AA44-62982F65DC35 @default.
- Q98603674 P1476 Q98603674-C2A3E14E-949E-4D94-A671-258161C79A49 @default.
- Q98603674 P2899 Q98603674-1D5DB4E8-F0C0-49DB-930A-4E5163AC9ED3 @default.
- Q98603674 P3098 Q98603674-4F861CD2-A86B-4295-B9FD-F82492D6C831 @default.
- Q98603674 P31 Q98603674-866F4A02-F85E-49B4-9720-5371D9500F9A @default.
- Q98603674 P580 Q98603674-D8BDA62B-51F0-4863-9A9B-98C69AA9AACD @default.
- Q98603674 P582 Q98603674-34484D8D-BE7E-4E29-989E-7F7638DB0849 @default.
- Q98603674 P6099 Q98603674-034DA430-4C07-4990-8B97-D8F578967FEF @default.
- Q98603674 P8005 Q98603674-4EFD3A41-F0B6-4DED-8934-7495BCE53EBA @default.
- Q98603674 P8363 Q98603674-EF917D47-DBCE-4729-8EA3-7D7FE2E08ADC @default.
- Q98603674 P1132 "+528" @default.
- Q98603674 P1476 "A Two-Part, Phase II, Multi-center Study of the ERK Inhibitor Ulixertinib (BVD-523) for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations" @default.
- Q98603674 P2899 "+18" @default.
- Q98603674 P3098 "NCT04488003" @default.
- Q98603674 P31 Q30612 @default.
- Q98603674 P580 "2020-10-01T00:00:00Z" @default.
- Q98603674 P582 "2023-08-01T00:00:00Z" @default.
- Q98603674 P6099 Q42824440 @default.
- Q98603674 P8005 Q76649614 @default.
- Q98603674 P8363 Q78089383 @default.